Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations

According to published in vitro studies, cytochrome P450 3A4 catalyzes montelukast 21-hydroxylation (M5 formation), whereas CYP2C9 catalyzes 36-hydroxylation (M6), the primary step in the main metabolic pathway of montelukast. However, montelukast is a selective competitive CYP2C8 inhibitor, and our recent in vivo studies suggest that CYP2C8 is involved in its metabolism. We therefore reevaluated the contributions of different cytochrome P450 (P450) enzymes, particularly that of CYP2C8, to the hepatic microsomal metabolism of montelukast using clinically relevant substrate concentrations in vitro. The effects of P450 isoform inhibitors on montelukast metabolism were examined using pooled human liver microsomes, and montelukast oxidations by human recombinant CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 were investigated. The results verified the central role of CYP3A4 in M5 formation. The CYP2C8 inhibitors gemfibrozil 1-O-β glucuronide and trimethoprim inhibited the depletion of 0.02 μM montelukast and formation of M6 from 0.05 μM montelukast more potently than did the CYP2C9 inhibitor sulfaphenazole. Likewise, recombinant CYP2C8 catalyzed montelukast depletion and M6 formation at a 6 times higher intrinsic clearance than did CYP2C9, whereas other P450 isoforms produced no M6. On the basis of depletion of 0.02 μM montelukast, CYP2C8 was estimated to account for 72% of the oxidative metabolism of montelukast in vivo, with a 16% contribution for CYP3A4 and 12% for CYP2C9. Moreover, CYP2C8 catalyzed the further metabolism of M6 more actively than did any other P450. In conclusion, CYP2C8 plays a major role in the main metabolic pathway of montelukast at clinically relevant montelukast concentrations in vitro.

[1]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[2]  A. Parkinson,et al.  Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. , 1997, Archives of biochemistry and biophysics.

[3]  P. Neuvonen,et al.  TRIMETHOPRIM AND SULFAMETHOXAZOLE ARE SELECTIVE INHIBITORS OF CYP 2 C 8 AND CYP 2 C 9 , RESPECTIVELY , 2002 .

[4]  W. Trager,et al.  Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[5]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[6]  C. Emoto,et al.  Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: The effect of the expression of cytochrome b5 with recombinant P450 enzymes , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  X. Xu,et al.  Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[9]  Eric F. Johnson,et al.  Determinants of Cytochrome P450 2C8 Substrate Binding , 2008, Journal of Biological Chemistry.

[10]  P. Neuvonen,et al.  Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone , 2006, European Journal of Clinical Pharmacology.

[11]  R. Obach,et al.  Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8 , 2005, Journal of clinical pharmacology.

[12]  M. Eichelbaum,et al.  Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[13]  C David Stout,et al.  Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.

[14]  M. Niemi,et al.  Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast , 2010, Clinical pharmacology and therapeutics.

[15]  R Scott Obach,et al.  SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST , 2005, Drug Metabolism and Disposition.

[16]  P. Neuvonen,et al.  Gemfibrozil considerably increases the plasma concentrations of rosiglitazone , 2003, Diabetologia.

[17]  K. Hara,et al.  Determination of montelukast sodium in human plasma by column-switching high-performance liquid chromatography with fluorescence detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[18]  A. Y. Lu,et al.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[19]  R R Miller,et al.  Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[20]  R Scott Obach,et al.  Drug metabolism and drug interactions: application and clinical value of in vitro models. , 2003, Current drug metabolism.

[21]  C L Crespi,et al.  The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future. , 1999, Pharmacology & therapeutics.

[22]  Ji-Young Park,et al.  Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. , 2007, British journal of clinical pharmacology.

[23]  Stefan Offermanns,et al.  International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B) , 2011, Pharmacological Reviews.

[24]  D. Back,et al.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. , 1998, British journal of clinical pharmacology.

[25]  Honglu Zhang,et al.  A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[26]  M. Niemi,et al.  The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism‐based Inhibition of CYP2C8 In Vivo , 2008, Clinical pharmacology and therapeutics.

[27]  A. D. Rodrigues,et al.  GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.

[28]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[29]  Aleksandra Galetin,et al.  Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.

[30]  Claire Strain-Damerell,et al.  Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions , 2009, Drug Metabolism and Disposition.

[31]  B. Gertz,et al.  Pharmacokinetics, Bioavailability, and Safety of Montelukast Sodium (MK-0476) in Healthy Males and Females , 1996, Pharmaceutical Research.

[32]  P. Neuvonen,et al.  Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide , 2003, Diabetologia.

[33]  G. Smith,et al.  Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  P. Neuvonen,et al.  CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe , 2009, Drug Metabolism and Disposition.

[35]  M. Merz,et al.  Pharmacokinetics and bioavailability of montelukast sodium (MK‐0476) in healthy young and elderly volunteers , 1997, Biopharmaceutics & drug disposition.

[36]  P. Neuvonen,et al.  Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[37]  Y. Berger,et al.  Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[38]  P. Neuvonen,et al.  Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide , 2006, Clinical pharmacology and therapeutics.